How do you approach treatment for a patient with a biochemical relapse while on maintenance lenalidomide after autologous stem cell transplant for multiple myeloma?
What factors (i.e. timing from transplant, dose, prior therapy) impact your decision?
Answer from: Medical Oncologist at Academic Institution
Biochemical relapse (i.e. increase in M-spike or light chains meeting criteria for progression on two occasions without clinical progression) is an indication for starting treatment in my opinion. I have seen some recommend increasing the dose of lenalidomide to 25 mg in the hopes this will bring di...
Comments
Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center Agree on all fronts with @Ben Derman's excellent r...
Medical Oncologist at Northwest Georgia Oncology Centers Our patients typically receive Dara RVD per GRIFFI...
Agree on all fronts with @Ben Derman's excellent r...
Our patients typically receive Dara RVD per GRIFFI...